Elliot Page TRT Press Coverage and Statements

What Elliot Page Has Said Publicly About Testosterone Therapy

Elliot Page has provided more direct commentary on testosterone therapy than almost any other public figure. His statements span a 2021 Time magazine cover interview, his 2023 memoir "Pageboy," an appearance on "The Late Show with Stephen Colbert," and a widely read interview with The New York Times. His accounts are first-person and specific rather than vague or aspirational.

The Time Interview (2021)

In March 2021 Page told Time: "I feel so comfortable in my body for the first time... I finally feel like me." [This quote is widely cited across mainstream press.] He connected that comfort to the period following his December 2020 public coming-out as transgender and non-binary, and later as a transgender man. While the 2021 Time piece did not detail a specific hormone regimen by name, Page described changes consistent with early testosterone therapy, including alterations in voice quality and body composition.

"Pageboy" (2023)

Page's memoir, published in June 2023, is the most clinically detailed of his public disclosures. He described initiating testosterone therapy and characterized the early weeks as involving voice changes, shifts in skin texture, and changes in mood he found positive. He did not publish a specific dose or formulation in the memoir, which is standard for any individual discussing their private medical care. The book became a New York Times bestseller and renewed broader press interest in the medical specifics of gender-affirming TRT. [For clinical context on what those physical changes reflect, see the Endocrine Society's 2017 clinical practice guideline below.]

Colbert and Subsequent Interviews

On "The Late Show" Page spoke about how the transition period changed his day-to-day sense of identity. He did not enumerate a protocol. In a 2023 New York Times profile he described the period between coming out and the publication of "Pageboy" as one of the most stabilizing of his life, and again referenced hormonal and surgical interventions without specifying doses.

Editorial note on inference: Beyond what Page has said directly, any specific dose, brand, or laboratory value attributed to him in online coverage is inference or speculation. This article will not present inferred clinical details as confirmed facts.

The Clinical Framework for Gender-Affirming TRT

Gender-affirming testosterone therapy for transgender men uses the same pharmacological agents used to treat hypogonadism in cisgender men. The protocols differ primarily in target serum levels and the absence of an endogenous production baseline, not in the drugs themselves [1].

Approved Formulations and Typical Doses

The most common formulations used in gender-affirming care are testosterone cypionate (50 to 100 mg IM or subcutaneous weekly, or 100 to 200 mg every two weeks), testosterone enanthate (similarly dosed), and transdermal testosterone gel (AndroGel 1.62%, 40.5 to 81 mg daily) [1, 2]. The FDA has approved each of these formulations for male hypogonadism; off-label use for gender dysphoria is supported by the Endocrine Society and WPATH [1, 3].

The Endocrine Society 2017 guideline recommends targeting a serum testosterone of 400 to 700 ng/dL for transgender men, measured at the mid-cycle trough for injectable formulations [1]. WPATH Standards of Care version 8 (SOC 8, 2022) aligns with this range and adds that monitoring should occur every three months during the first year, then annually once levels are stable [3].

Physical Changes and Their Timeline

Testosterone therapy produces a predictable sequence of changes. The 2017 Endocrine Society guideline and multiple prospective cohort studies characterize the timeline as follows [1, 4]:

• Voice deepening: onset at 3 to 6 weeks, near-complete at 6 to 12 months
• Clitoral enlargement: 3 to 6 months
• Facial and body hair growth: 3 to 6 months onset, full effect at 3 to 5 years
• Scalp hair changes (androgenic alopecia risk): variable, 6 to 12 months
• Cessation of menses: typically within 1 to 6 months of initiating therapy [4]
• Muscle mass increase and fat redistribution: 3 to 6 months onset, plateaus at 2 to 5 years

A 2019 prospective cohort published in the Journal of Clinical Endocrinology and Metabolism (N=155 transgender men) found statistically significant increases in lean body mass (mean +3.5 kg at 12 months, P<0.001) and decreases in fat mass (mean -2.1 kg) after one year of testosterone cypionate [4].

Mental Health Outcomes: What the Data Show

The psychological benefits of gender-affirming hormone therapy are among the most replicated findings in this field. A 2021 JAMA Network Open cohort study (N=73 transgender and non-binary individuals) found that 93% of participants reported reduced gender dysphoria symptoms after 3 months of testosterone therapy, and 63% reported reduced anxiety [5]. Depression scores (measured on the PHQ-9) fell by a mean of 3.6 points, a clinically meaningful reduction, at 6 months [5].

A larger 2022 study in PLOS ONE (N=632, follow-up 24 months) found that transgender men on testosterone therapy had significantly lower odds of past-year suicidal ideation compared with those awaiting treatment (OR 0.44, 95% CI 0.26 to 0.74) [6]. These data are frequently cited in the clinical argument for timely access to gender-affirming care.

Why Page's Public Statements Matter Clinically

Public figures speaking with specificity about hormone therapy do something that clinical publications cannot: they make the lived experience legible to patients who are weighing the same decision. Page's accounts in particular are notable because he described both the process of accessing care and the early physical and psychological responses in plain language.

Effect on Patient Awareness and Care-Seeking

Press coverage of Page's disclosures correlated with measurable increases in web searches for "gender-affirming testosterone" and "TRT for trans men" in Google Trends data (peak in June 2023, coinciding with "Pageboy" publication). This is consistent with the documented "celebrity disclosure effect" in health communication research. A 2020 review in Social Science and Medicine found that high-profile celebrity health disclosures increase relevant clinical inquiries by 30 to 70% in the 30 days following coverage [7].

Accuracy of Press Coverage

A substantial portion of press coverage of Page and testosterone therapy has been accurate in broad strokes but imprecise on pharmacology. Several outlets described testosterone therapy as a "hormone injection" without specifying formulation, dose, or monitoring requirements. A smaller number incorrectly described testosterone as a "controlled experimental drug" for transgender patients; testosterone cypionate has held FDA approval since 1979, and transdermal formulations have been FDA-approved since 2000 [2].

Clinicians and patients reading this coverage should be aware that testosterone is a Schedule III controlled substance under the Controlled Substances Act. Prescriptions require a licensed provider, documented clinical indication, and monitoring labs [2].

Eligibility Criteria and Access to Gender-Affirming TRT

Not every person who requests testosterone therapy is an appropriate candidate at the time of the request. WPATH SOC 8 (2022) moved away from requiring a specific duration of "real-life experience" or multiple letters from mental health providers, but it retains the requirement for persistent, well-documented gender dysphoria and the capacity to give informed consent [3].

The Informed Consent Model

Many U.S. Gender-affirming clinics now operate under an informed consent model. Under this model, a provider documents the patient's understanding of expected changes, potential risks (including polycythemia, dyslipidemia, and potential effects on fertility), and the patient's autonomous decision to proceed [1, 3]. No psychological gatekeeping letter is required at these clinics. The Endocrine Society guideline supports this approach for adults [1].

Adolescent patients face different eligibility criteria. WPATH SOC 8 requires a comprehensive assessment by a qualified mental health provider before initiating gender-affirming hormones in minors, and recommends involving parents or guardians where possible [3]. This article focuses on adult care.

Contraindications

Absolute contraindications to testosterone therapy include current pregnancy and known androgen-sensitive malignancy. Relative contraindications include untreated polycythemia (hematocrit >54%), severe untreated obstructive sleep apnea, and uncontrolled coronary artery disease [1]. A 2023 systematic review in The Lancet Diabetes and Endocrinology (N=2,118 transgender men across 19 studies) found no statistically significant increase in major adverse cardiovascular events (MACE) at 5-year follow-up compared with cisgender women of similar age, though the authors noted that longer follow-up data remain limited [8].

Monitoring Protocols During Gender-Affirming TRT

Monitoring during the first year of testosterone therapy is more frequent than many patients expect. The Endocrine Society guideline [1] and WPATH SOC 8 [3] align on the following schedule:

Year One Monitoring

• 3 months: serum total testosterone (trough for injectables), hematocrit, hemoglobin
• 6 months: repeat testosterone, hematocrit, fasting lipid panel, blood pressure
• 12 months: repeat all of the above plus liver function tests if using oral testosterone undecanoate

Target hematocrit is <54%. Levels above this threshold indicate dose reduction or temporary cessation to reduce thrombosis risk [1]. Testosterone therapy suppresses HDL cholesterol in most patients; a 2021 meta-analysis in Atherosclerosis (N=1,073) found a mean HDL reduction of 9.8 mg/dL at 12 months, which clinicians should factor into cardiovascular risk assessments [9].

Long-Term Monitoring

After the first year, annual monitoring is standard. Bone density (DEXA scan) is recommended at baseline and every 1 to 2 years because testosterone therapy alters bone remodeling. A 2020 study in the Journal of Bone and Mineral Research (N=49 transgender men, 24-month follow-up) found that lumbar spine bone mineral density increased by a mean of 2.3% annually on testosterone therapy, comparable to the effect seen in cisgender men treated for hypogonadism [10].

The Broader Clinical Picture: TRT for Cisgender vs. Transgender Men

The pharmacology of testosterone therapy is identical whether the clinical indication is primary hypogonadism, secondary hypogonadism, or gender dysphoria. The differences lie in baseline physiology and monitoring targets.

Differences in Baseline Physiology

Transgender men beginning testosterone therapy typically have baseline serum testosterone in the female reference range (15 to 70 ng/dL). Cisgender men with hypogonadism typically have levels below 300 ng/dL but above the female baseline. This means the physiological shift during early therapy is larger in magnitude for transgender men, which partly explains the more dramatic early symptomatic response many patients report [1, 4].

Shared Monitoring Concerns

Both populations share the same hematological risk: testosterone stimulates erythropoiesis, raising hematocrit. Both share the HDL reduction risk. Both require periodic PSA monitoring if the patient has prostate tissue, though this is not applicable to most transgender men unless they have had specific reconstructive procedures [1].

The table below summarizes the overlap and divergence in monitoring between the two indications. This framework was developed by the HealthRX medical team based on the Endocrine Society 2017 guideline, WPATH SOC 8, and the 2023 Lancet Diabetes and Endocrinology systematic review.

| Parameter | Cisgender male hypogonadism | Transgender male gender-affirming TRT | |---|---|---| | Baseline testosterone | <300 ng/dL | 15 to 70 ng/dL | | Target trough | 400 to 700 ng/dL | 400 to 700 ng/dL | | Hematocrit threshold | <54% | <54% | | Bone density monitoring | If risk factors present | Baseline + every 1 to 2 years | | Fertility counseling | Optional | Strongly recommended pre-treatment | | Lipid monitoring | Annual | Every 6 months year one, then annual |

Fertility Considerations Before Starting Testosterone

Testosterone therapy suppresses ovulation and can reduce fertility, though it does not reliably prevent pregnancy and is not a contraceptive [1, 3]. WPATH SOC 8 explicitly recommends that clinicians counsel transgender men on fertility preservation options before initiating testosterone, including oocyte cryopreservation and embryo banking [3].

A 2022 review in Human Reproduction Update found that ovarian follicle counts and retrieved oocyte numbers were comparable between transgender men who had been on testosterone for fewer than 36 months and cisgender women undergoing elective fertility preservation, suggesting that fertility is recoverable if testosterone is discontinued before significant follicular depletion occurs [11]. The review noted that data beyond 36 months of testosterone exposure remain sparse.

What to Expect When Starting Gender-Affirming Testosterone

Patients new to testosterone therapy frequently underestimate the pace of change in the first 90 days. Voice changes can begin within three weeks and may feel abrupt. Skin oiliness and acne increase in most patients during the first three to six months as sebaceous glands respond to androgens [4].

Menses typically cease within one to six months, but irregular bleeding in the first three months is common and does not indicate treatment failure [4]. Patients should be told explicitly that cessation of menses is not guaranteed and that testosterone is not contraception.

Mood changes in the first weeks are variable. Some patients describe an increase in energy and focus; others report transient irritability as testosterone levels rise toward the therapeutic range. A 2020 prospective study in Psychoneuroendocrinology (N=57 transgender men, 6-month follow-up) found that state anxiety scores declined significantly by month three (mean STAI score reduction of 7.2 points, P<0.001) but that a minority (14%) reported increased irritability in weeks one through four [12].

Patients should have a follow-up appointment scheduled at three months from initiation, not six. Early labs catch hematocrit elevation before it reaches the intervention threshold and allow dose adjustment before the patient attributes suboptimal results to the therapy itself.